Differential Inhibitory Effects of CysLT1 Receptor Antagonists on P2Y6 Receptor-Mediated Signaling and Ion Transport in Human Bronchial Epithelia
Authors:
Open Access
- 22 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22363
Abstract
Cysteinyl leukotriene (CysLT) is one of the proinflammatory mediators released by the bronchi during inflammation. CysLTs exert their biological effects via specific G-protein-coupled receptors. CysLT1 receptor antagonists are available for clinical use for the treatment of asthma. Recently, crosstalk between CysLT1 and P2Y6 receptors has been delineated. P2Y receptors are expressed in apical and/or basolateral membranes of virtually all polarized epithelia to control the transport of fluid and electrolytes. Previous research suggests that CysLT1 receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. However, the detailed molecular mechanism underlying the inhibition remains unresolved. In this study, western blot analysis confirmed that both CysLT1 and P2Y6 receptors were expressed in the human bronchial epithelial cell line 16HBE14o-. All three CysLT1 antagonists inhibited the uridine diphosphate (UDP)-evoked ISC, but only montelukast inhibited the UDP-evoked [Ca2+]i increase. In the presence of forskolin or 8-bromoadenosine 3′5′ cyclic monophosphate (8-Br-cAMP), the UDP-induced ISC was potentiated but was reduced by pranlukast and zafirlukast but not montelukast. Pranlukast inhibited the UDP-evoked ISC potentiated by an Epac activator, 8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate (8-CPT-2′-O-Me-cAMP), while montelukast and zafirlukast had no such effect. Pranlukast inhibited the real-time increase in cAMP changes activated by 8-CPT-2′-O-Me-cAMP as monitored by fluorescence resonance energy transfer imaging. Zafirlukast inhibited the UDP-induced ISC potentiated by N6- Phenyladenosine- 3′, 5′- cyclic monophosphorothioate, Sp- isomer (Sp-6-Phe-cAMP; a PKA activator) and UDP-activated PKA activity. In summary, our data strongly suggest for the first time that in human airway epithelia, the three specific CysLT1 receptor antagonists exert differential inhibitory effects on P2Y6 receptor-coupled Ca2+ signaling pathways and the potentiating effect on ISC mediated by cAMP and Epac, leading to the modulation of ion transport activities across the epithelia.Keywords
This publication has 50 references indexed in Scilit:
- Polarized Secretion of Interleukin (IL)-6 and IL-8 by Human Airway Epithelia 16HBE14o- Cells in Response to Cationic Polypeptide ChallengePLOS ONE, 2010
- Epac1 mediates protein kinase A–independent mechanism of forskolin-activated intestinal chloride secretionJournal of General Physiology, 2009
- EPAC proteins transduce diverse cellular actions of cAMPBritish Journal of Pharmacology, 2009
- Store-operated cyclic AMP signalling mediated by STIM1Nature Cell Biology, 2009
- A Comparison of Donor-Acceptor Pairs for Genetically Encoded FRET Sensors: Application to the Epac cAMP Sensor as an ExamplePLOS ONE, 2008
- Spatiotemporal Coupling of cAMP Transporter to CFTR Chloride Channel Function in the Gut EpitheliaCell, 2007
- CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammationJournal of Cell Science, 2005
- Purinergic P2Y6 Receptors Induce Ca2+ and CFTR Dependent Cl- Secretion in Mouse TracheaCellular Physiology and Biochemistry, 2005
- The pyrimidinergic P2Y6 receptor mediates a novel release of proinflammatory cytokines and chemokines in monocytic cells stimulated with UDPBiochemical and Biophysical Research Communications, 2005
- Architecture of P2Y Nucleotide Receptors: Structural Comparison Based on Sequence Analysis, Mutagenesis, and Homology ModelingJournal of Medicinal Chemistry, 2004